Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma
Authors
Keywords
ALK, ALCL, Drug resistance, ALK inhibitors, Crizotinib, CH5424802
Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume 140, Issue 4, Pages 589-598
Publisher
Springer Nature
Online
2014-02-07
DOI
10.1007/s00432-014-1589-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
- (2013) Takashi Seto et al. LANCET ONCOLOGY
- Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
- (2013) Yael P Mossé et al. LANCET ONCOLOGY
- Brentuximab Vedotin and Crizotinib in Anaplastic Large-Cell Lymphoma
- (2012) Kelley V. Foyil et al. CANCER JOURNAL
- FLT-PET Is Superior to FDG-PET for Very Early Response Prediction in NPM-ALK-Positive Lymphoma Treated with Targeted Therapy
- (2012) Z. Li et al. CANCER RESEARCH
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- Anaplastic lymphoma kinase as a therapeutic target
- (2012) Anna Kruczynski et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
- (2012) D Ross Camidge et al. LANCET ONCOLOGY
- Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors
- (2012) M. Ceccon et al. MOLECULAR CANCER RESEARCH
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
- (2011) Hiroshi Sakamoto et al. CANCER CELL
- A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
- (2011) T. Sasaki et al. CANCER RESEARCH
- Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen
- (2011) Sen Zhang et al. Chemical Biology & Drug Design
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
- (2011) R. Katayama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors
- (2010) Roberto T. Bossi et al. BIOCHEMISTRY
- Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group
- (2010) N. Schmitz et al. BLOOD
- The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers
- (2010) T. Sasaki et al. CANCER RESEARCH
- Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene
- (2010) Z. Chen et al. CANCER RESEARCH
- Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer
- (2010) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic lymphoma kinase: signalling in development and disease
- (2009) Ruth H. Palmer et al. BIOCHEMICAL JOURNAL
- ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project
- (2008) K. J. Savage et al. BLOOD
- International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes
- (2008) JOURNAL OF CLINICAL ONCOLOGY
- Identification of ALK as a major familial neuroblastoma predisposition gene
- (2008) Yaël P. Mossé et al. NATURE
- Activating mutations in ALK provide a therapeutic target in neuroblastoma
- (2008) Rani E. George et al. NATURE
- Oncogenic mutations of ALK kinase in neuroblastoma
- (2008) Yuyan Chen et al. NATURE
- Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
- (2008) Isabelle Janoueix-Lerosey et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now